Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 8/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 5/20 | 0.38 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.38 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.36 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3677579 | 0.88 | MGAM (0.42) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL28100172 | 0.86 | MGAM (0.65) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL7097459 | 0.82 | MGAM (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL18130134 | 0.82 | MGAM (0.46) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL4466465 | 0.81 | PLOD2 (0.39) | HSD17B10FAAHCES1CES2MEN1 | |
| SCHEMBL129536 | 0.80 | MGAM (0.44) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL1407070 | 0.80 | MGAM (0.44) | MGAMGAASIMGAM2TSHR | |
| SCHEMBL27676526 | 0.80 | TSHR (0.62) | TSHRHSD17B10FAAHCES1CES2 | |
| SCHEMBL9468556 | 0.80 | TSHR (0.54) | TSHRHSD17B10FAAHCES1CES2 | |
| SCHEMBL18643782 | 0.79 | PLOD2 (0.38) | HSD17B10FAAHCES1CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 407 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110550-A1 | COMPLEX FOR GENE DELIVERY | 전남대학교산학협력단 | 2025-05-30 | — | — | WO | claimed |
| CN-116632340-A | Lithium ion electrolyte for inhibiting flatulence, preparation method thereof and electrochemical device | 湖南法恩莱特新能源科技有限公司 | 2023-08-22 | — | — | CN | claimed |
| CN-110832110-A | Method for producing a metal nanoparticle layer and use thereof in decorative or security elements | 巴斯夫欧洲公司 | 2020-02-21 | — | — | CN | claimed |
| CN-107876092-A | The high stability titanium catalyst of ester exchange carbonate synthesis benzene methyl and diphenyl carbonate | 华东理工大学 | 2018-04-06 | — | — | CN | claimed |
| CN-107417719-A | A kind of titanium chelate catalyst for being used for carbonate synthesis benzene methyl and diphenyl carbonate | 华东理工大学 | 2017-12-01 | — | — | CN | claimed |
| EP-2459182-B1 | INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT | UNIV OF ZÜRICH (CH) | 2017-09-06 | — | — | EP | claimed |
| EP-2459182-A1 | INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT | University of Zürich (CH) | 2012-06-06 | — | — | EP | claimed |
| WO-2011012283-A1 | INJECTABLE FORMULATION FOR TREATMENT AND PROTECTION OF PATIENTS HAVING AN INFLAMMATORY REACTION OR AN ISCHEMIA-REPERFUSION EVENT | UNIVERSITY OF ZURICH (CH) | 2011-02-03 | — | — | WO | claimed |
| CN-1455663-A | Novel aerosol formulation containing polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-11-12 | — | — | CN | claimed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-0135491-B1 | HERBICIDAL 2,6-BIS-FLUOROMETHYL-DIHYDROPYRIDINE-3,5-DICARBOXYLIC ACID ESTERS | MONSANTO COMPANY (US) | 1989-01-25 | — | — | EP | claimed |
| EP-0135491-A1 | Herbicidal 2,6-bis-fluoromethyl-dihydropyridine-3,5-dicarboxylic acid esters | MONSANTO COMPANY (US) | 1985-03-27 | — | — | EP | claimed |
| JP-9227440-A | — | — | None | — | — | JP | disclosed |
| US-12544382-B2 | 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2026-02-10 | — | — | US | disclosed |
| WO-2025110550-A1 | COMPLEX FOR GENE DELIVERY | 전남대학교산학협력단 | 2025-05-30 | — | — | WO | disclosed |
| EP-0133612-A2 | Substituted 2,6-substituted pyridine compounds | MONSANTO COMPANY (US) | 1985-02-27 | — | — | EP | disclosed |
| US-4042603-A | SUBSTITUTED DIBENZOFURAN OR 9-FLUORENONE FROM A DIPHENYL ETHER OR BENZOPHENONE | UBE INDUSTRIES, LTD. (JA) | 1977-08-16 | — | — | US | disclosed |
| US-3933423-A | Azoic dyeing of leather | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544382-B2 | 2, 4, 6-tri-substituted pyrimidine compound as ATR kinase inhibitor | ATR, CHEK1, CHEK2 | MGAM 4453/4885GAA 2648/4885SI 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.